Table 3

Validation of drug intervention endpoints: Cholesterol lowering and CHD

Association of cholesterol level and CHD from Framingham study, data for total population
Serum cholesterolRelative risk (Observed/Expected × 100)
1st quartile (<193 mg/100 ml)57
2nd quartile (194–219 mg/100 ml)85
3rd quartile (220–249 mg/100 ml)102
4th quartile (>250 mg/100 ml)152
Effect of drug intervention on cholesterol level, leading to approval by FDA for prevention of CHD
• Simvistatin decreased serum cholesterol by an average of 26% compared with placebo controls
Effect of cholesterol lowering intervention on CHD, meta-analysis of trials >2 yrs in duration
• For every 10% of cholesterol lowering, CHD mortality was reduced by 13% (P < 0.002) and total mortality was reduced by 10% (P < 0.03)